Oxford BioDynamics PLC Board transition (8471O)
June 03 2020 - 7:30AM
UK Regulatory
TIDMOBD
RNS Number : 8471O
Oxford BioDynamics PLC
03 June 2020
3 June 2020
Oxford BioDynamics Plc
( "OBD" or the "Company" and, together with its subsidiaries,
the "Group")
Board Transition
-- Industry expert Dr Peter Pack, Non-Executive Director,
appointed as Non-Executive Chairman, succeeding Stephen Diggle
Oxford BioDynamics Plc (AIM:OBD), a biotechnology company
focused on the discovery and development of epigenetic biomarkers,
based on regulatory 3D genome architecture, using its liquid biopsy
platform EpiSwitch ä , today announces that Dr Peter Pack,
Independent Non-Executive Director, has been appointed as
Independent Non-Executive Chairman of Oxford BioDynamics. Stephen
Diggle, who was holding the position of Interim Chairman, will
transition to the role of Non-Executive Director.
Peter brings over 27 years of international life sciences
experience to his new role. He started his career at MorphoSys AG
as co-inventor of one of the most commercially successful human
antibody libraries. Following this, he was co-founder and CEO of
MTM laboratories AG (Heidelberg, Germany and Westborough, US),
which is now part of Roche Diagnostics. During his time as CEO,
Peter successfully established a fully integrated diagnostic
company from scratch, developing and internationally
commercialising novel, biomarker-based CINtec(R) tests for the
screening and diagnosis of cervical cancer.
Between 2015 and 2019 he headed the Cambridge, UK-based
therapeutics company Crescendo Biologics Ltd, leading its
transition from a transgenic platform company to a developer of
multispecific biologics with an internal, late stage preclinical
pipeline in oncology. Peter has also been a board member of the
transfection specialist PolyPlus (Strasbourg, France) and the
biomarker company Signature Diagnostics (Potsdam, Germany) which is
also now part of Roche Diagnostics.
Peter joined the OBD Board in April 2019 and in his first year
as a Non-Executive Director has provided excellent support and
challenge to the Executive Directors, as well as developing a deep
understanding of OBD's technology and business.
Dr Peter Pack, Non-Executive Chairman, Oxford BioDynamics, said:
"It has been a pleasure to work with the Board and management team
since I joined as a Non-Executive last year. The Company has grown
significantly in the past few years, increasing its international
footprint, its portfolio of intellectual property, and the range of
global pharma and biopharma companies on its roster. This is an
exciting time for OBD as we plan for further commercialisation of
the EpiSwitch(TM) platform. I look forward to leading the Board and
supporting the new CEO Jon Burrows and the rest of his team."
Dr Jon Burrows, CEO of Oxford BioDynamics, added: "I am
delighted that Peter is taking on the role of Non-Executive
Chairman. His significant commercial experience will be invaluable
in his new role as Chairman and I look forward to him supporting
the Company as we seek to deliver significant success for
shareholders. On behalf of the whole Board, I would also like to
thank Stephen Diggle for his commitment and leadership in the
position of Interim Chairman over the last year and look forward to
his continued membership of the Board as a Non-Executive
Director."
Stephen Diggle, Non-Executive Director, Oxford BioDynamics,
said: "I'm very pleased to be stepping down as Interim Chairman to
make way for Peter Pack and resume my role as a Non-Executive
Director. Since joining the Board Peter has demonstrated the
knowledge, acumen and judgement required to be Chairman of a
company with the potential of Oxford BioDynamics."
-ENDS-
For further details please contact:
Oxford BioDynamics Plc
Jon Burrows, CEO
Alexandre Akoulitchev,
CSO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Advisor and
Broker
Stephane Auton
Edward Mansfield
John More +44 (0)20 7408 4090
FTI Consulting
Financial Public Relations
Adviser
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for
Enterprise: Innovation. The Queen's Awards for Enterprise are the
most prestigious awards for UK businesses.
The Company is headquartered in the UK and listed on the London
Stock Exchange's AIM under the ticker "OBD". For more information
please visit www.oxfordbiodynamics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOALXLFBBQLFBBD
(END) Dow Jones Newswires
June 03, 2020 08:30 ET (12:30 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024